ECE2019 Poster Presentations Calcium and Bone 2 (59 abstracts)
Effect of hyperparathyroidism on coagulation: an analysis by modified rotation thromboelastogram (ROTEM)
Goknur Yorulmaz 1 , Ahmet Toygar Kalkan 1 , Aysen Akalin 1 , Elif Sevil Alagüney 1 , Eren Gunduz 1 , Bartu Badak 1 , Olga Meltem Akay 2 , Betul Aydin Buyruk 1 , Nur Kebapci 1 , Belgin Efe 1 & Muzaffer Bilgin 1
1Osmangazi University, Eskisehir, Turkey; 2Koc University, İstanbul, Turkey.
Introduction: Parathyroid hormone (PTH) is a peptide-based hormone that controls the level of ionized calcium in blood and extracellular fluids. Hemostasis is regulated by the balance between natural stimulants and inhibitors on platelet functions. Disruption of the balance between inhibitor and stimulants leads to thrombosis or bleeding. There are studies on the association of hyperparathyroidism with thrombotic disease. Thromboelastography is a method of evaluating the whole process of coagulation from the beginning of the clot formation to fibrinolysis. By measuring the viscoelasticity of blood clots by thromboelastography, we can provide information on the effect of various factors such as plasma factors, platelets and leukocytes in the whole stage of coagulation and fibrinolytic processes.
Material and methods:: Patients who were scheduled for operation due to hyperparathyroidism were included in the study. Thromboelastographic evaluation was performed in the hyperparathyroidic preoperative period and postoperative periods. 30 patients were planned to be included in our study who do not have hematologic, liver and kidney disease and without antiplatelet and anticoagulant use. We wanted to share the data of the first 7 patients as a preliminary evaluation, since the study was not completed and patient recruitment continued.
Results: The preoperative and post-operative thromboelastography results of the patients did not Show a statistical difference (P>0.005) (Table 1). There was not a correlation between calcium values and thromboelastogram results.
| Mean ± Std. Dev. | |||
| Before | After | P* | |
| ICT | 190±32,5 | 256,71±52,19 | 0.09 |
| ICFT | 101,43±34,55 | 97,71±46,78 | 1.00 |
| IMCF | 60,86±4,67 | 64,71±10,03 | 0.25 |
| ECT | 82,14±4,98 | 69,57±40,34 | 0.61 |
| ECFT | 108,86±41,59 | 130,43±55,98 | 0.24 |
| eMCF | 63,43±5 | 67,57±7,59 | 0.18 |
| Ca | 11,40±0,52 | 9,00±0,33 | 0.018 |
| Plt | 235428,57±81985,48 | 265000,00±90432,295 | 0.138 |
| PTH | 472,15±57,10 | 42,30±1,83 | 0.018 |
Conclusion: Since the data we have covers a limited number of patients, we anticipate that we will reach more detailed information upon completion of our study. In the light of the results we obtained in the preliminary evaluation, we believe that the data we will provide as a result of the study will provide motivation for further studies.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more